Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2023 Publisher: Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216, Ingelheim am Rhein, Germany
Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).
The medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat inhaler.
Two actuations (puffs) from the Respimat inhaler comprise one medicinal dose.
The recommended dose is 5 microgram olodaterol given as two actuations (puffs) from the Respimat inhaler once daily, at the same time of the day.
The recommended dose should not be exceeded.
Elderly patients can use Striverdi Respimat at the recommended dose.
Patients with mild and moderate hepatic impairment can use Striverdi Respimat at the recommended dose.
There are no data available for use of Striverdi Respimat in patients with severe hepatic impairment.
Renally impaired patients can use Striverdi Respimat at the recommended dose. There is limited experience with the use of Striverdi Respimat in patients with severe renal impairment.
There is no relevant use of Striverdi Respimat in the paediatric population (under 18 years).
This medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat re-usable inhaler. Respimat is an inhaler device that generates a spray for inhalation. It is meant for use by a single patient and intended for multiple doses delivered by one cartridge.
The Respimat re-usable inhaler allows for replacement of the cartridge, and can be used with up to 6 cartridges.
Patients should read the instructions on how to use the Respimat re-usable inhaler before they start using Striverdi Respimat.
To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler by a physician or other health care professional.
The patient will need to use this inhaler only ONCE A DAY. Each time used take TWO ACTUATIONS (PUFFS).
Clean the mouthpiece including the metal part inside the mouthpiece with a damp cloth or tissue only, at least once a week.
Any minor discoloration in the mouthpiece does not affect the Respimat re-usable inhaler performance.
If necessary, wipe the outside of the Respimat re-usable inhaler with a damp cloth.
When the patient has used an inhaler with 6 cartridges, get a new Striverdi Respimat pack containing an inhaler.
1. Remove clear base:
2. Insert cartridge:
3. Track cartridge:
4. Turn:
5. Open:
6. Press:
The inhaler is now ready to use and will deliver 60 actuations (puffs) (30 doses).
TURN:
OPEN:
PRESS:
The dose indicator shows how many actuations (puffs) remain in the cartridge.
60 actuations (puffs) remaining.
Less than 10 actuations (puffs) remaining. Obtain a new cartridge.
The cartridge is used up. Turn the clear base to loosen it. The inhaler is now in a locked position. Pull off the cartridge from the inhaler. Insert a new cartridge until it clicks (refer to step 2). The new cartridge will stick out more than the very first cartridge (continue with step 3). Remember to put the clear base back to unlock the inhaler.
An overdose of olodaterol is likely to lead to exaggerated effects typical of beta2-adrenergic agonists, e.g. myocardial ischaemia, hypertension or hypotension, tachycardia, arrhythmias, palpitation, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasms, nausea, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis.
Treatment with Striverdi Respimat should be discontinued. Supportive and symptomatic treatment is indicated. Serious cases should be hospitalised. Use of cardioselective beta-blockers may be considered, but only subject to extreme caution since the use of beta-adrenergic blocker medication may provoke bronchospasm.
3 years.
In-use shelf life cartridge: 3 months.
In-use shelf-life inhaler: 1 year.
Recommended use: 6 cartridges per inhaler.
Note: The functioning of the RESPIMAT re-usable inhaler has been demonstrated in tests for 540 actuations (corresponding to 9 cartridges).
Do not freeze.
Type and material of the container in contact with the medicinal product:
Solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminium cylinder.
Each cartridge contains 4 ml inhalation solution.
Pack sizes and devices supplied:
Single pack: 1 Respimat re-usable inhaler and 1 cartridge, providing 60 actuations (puffs) (30 medicinal doses).
Triple pack: 1 Respimat re-usable inhaler and 3 cartridges, providing 60 actuations (puffs) (30 medicinal doses) each.
Single refill pack: 1 cartridge, providing 60 actuations (puffs) (30 medicinal doses).
Triple refill pack: 3 cartridges, providing 60 actuations (puffs) (30 medicinal doses) each.
Not all pack sizes may be marketed.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.